INTECH Investment Management’s Bicara Therapeutics BCAX Stock Holding History

INTECH Investment Management’s Portfolio BCAX Stock Details BCAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-8,767	Closed	-$260K	–	2141
2026 Q2	$260K	Buy	+8,767	New	+$196K	﹤0.01%	1655
2026 Q1	–	Sell	-14,103	Closed	-$237K	–	2385
2025 Q4	$237K	Buy	14,103 +65	+0.5%	+$1.11K	﹤0.01%	1880
2025 Q3	$222K	Sell	14,038 -13,635	-49%	-$153K	﹤0.01%	2003
2025 Q2	$257K	Buy	27,673 +10,927	+65%	+$130K	﹤0.01%	1963
2025 Q1	$218K	Buy	+16,746	New	+$222K	﹤0.01%	2046

Other funds holding BCAX

Red Tree Management Redwood City, California $117M AUM 89.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Nan Fung Trinity Central, Hong Kong, Hong Kong $1.04B AUM 32.17% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return

SEB Asset Management Stockholm $27B AUM

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

INTECH Investment Management's BCAX Position: Q3 2026 in Review

INTECH Investment Management sold out of Bicara Therapeutics (BCAX) in Q3 2026, closing a stake of 8,767 shares — an estimated $260K sold.

INTECH Investment Management first reported a position in BCAX in Q1 2025 and held it in 5 quarters. The position peaked at $260K in Q2 2026. 65 funds tracked by Wall St. Rank hold BCAX as of Q3 2026.

INTECH Investment Management reported no remaining Bicara Therapeutics position as of Q3 2026 after selling out during the quarter.
INTECH Investment Management sold 8,767 Bicara Therapeutics shares in Q3 2026, an estimated $260K.
INTECH Investment Management first reported a position in Bicara Therapeutics in Q1 2025 and held it in 5 quarters.
INTECH Investment Management's Bicara Therapeutics position peaked at $260K in Q2 2026.
65 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q3 2026.

Based on INTECH Investment Management's 13F filing for Q3 2026, filed 9 Nov 2026.